glp 1 gip dual agonist mechanism of action The GLP-1 and signaling at homeostasis Schematic illustration of monoagonists, dual
Description
Data on effectiveness

Gmez-Zorita S et al

At the same time, results arent guaranteed and vary from individual to individual

Some of these differences mirrored patterns observed for past-year use of GLP-1 and GLP-1/GIP medications for weight loss
For example, oral treatment with semaglutide for 68 weeks can lead to a weight loss of 17.4% in patients, with 89.2% of patients experiencing a weight loss of 5%
Although Glp1r expression is mostly localized to endothelial cells in the mouse aorta (29), other vascular cell types may express Glp1r under atherogenic conditions, making it difficult to pinpoint which cell type mediates the antiinflammatory effects of GLP-1 medicines